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Abstract
Studies involving women or women with SUDs for PrEP are limited even though in many areas of the
world women remain at high-risk for HIV acquisition. This study is to evaluate the impact of accuracy
of HIV risk perception on HIV risk behaviors changes over time among women with substance use
disorders in treatment, including sexual and injecting risk behaviors. This is a secondary analysis based
on a preference controlled un-blinded study. This study enrolled 165 cis- or trans-female volunteers
≥18 years old who were self-reported HIV-uninfected, had diagnosed SUDs, and were presenting
for or currently enrolled in drug treatment. 50.6% of participants (N=83) were categorized as
underestimating their HIV risk while 49.4% (N=81) were categorized as accurately/over-estimating
their HIV risk at baseline. We observed a positive association between underestimating HIV risk at
baseline and reduction of HIV risk behaviors over time. Though women who underestimated their
HIV risk did reduce their HIV risk behaviors to some extent over time, their HIV risk was still higher
than women who accurately or overestimated HIV risk at each subsequent visit. Some high-risk
behaviors persisted. The greatest impact of underestimating personal HIV risk on the self-reported
HIV risk behaviors was initially after baseline with reduced behavioral change over time, indicating
this impact on the change of HIV risk behaviors may be short-lived and fade away if no other
intervention is delivered. Though there was a sharp decrease in condomless sex over time among the
“underestimate” group, the proportion was above 50% throughout the period of observation, which
may be attributed to other determinants that affect women’s decisions of whether to use condom,
such as inability to negotiate with sexual partners. Studies collecting more detailed HIV risk behaviors
information and considering about other confounders, such as IPV, are needed to research the
intensity and duration of the effect of underestimating HIV risk on behavior changes.
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Introduction
Pre-exposure prophylaxis (PrEP), or the use of antiretroviral medications to prevent HIV infection, is
one of the promising tools to reduce HIV risk for HIV-uninfected individuals. Many placebo-controlled
clinical trials have demonstrated the efficacy of oral PrEP in reducing the risk of HIV transmission
among men who have sex with men (MSM) (Grant et al., 2010), serodiscordant heterosexual couples
(Baeten et al., 2012; Thigpen et al., 2012) and people who inject drugs (PWIDs) (Choopanya et al.,
2013). One theoretical concern about using PrEP as HIV prevention is the potential for risk

disinhibition or sexual risk compensation (Cassell, Halperin, Shelton, & Stanton, 2006; Pinkerton, 2001).
Concerns derived from the possibility that people would have an excessive optimism about the
protective effect of PrEP, and that will lead to increased risk behaviors. Similar concerns have been
raised regarding various HIV prevention efforts, including vaccines (Chesney, Chambers, & Kahn,
1997), male circumcision (Lagarde, Dirk, Puren, Reathe, & Bertran, 2003), and vaginal microbicides
(Foss, Vickerman, Heise, & Watts, 2003). Since PrEP does not totally eliminate the risk of HIV (or other
sexually transmitted infections) and requires daily use which makes adherence difficult for many
people, US guidelines on PrEP currently recommend that other HIV risk-reduction approaches,
particularly condoms, should be used alongside PrEP.

Women with substance use disorders (SUDs) experience high HIV risk due to substance use behaviors
(including injecting) and overlapping sex and drug use networks. Compared with women without SUD,
they disproportionately interact with the criminal justice system (CJS) (Drugs & Crime, 2018), engage
in transactional sex (Azim, Bontell, & Strathdee, 2015; Iversen, Page, Madden, & Maher, 2015), and
experience physical and sexual violence (Gilbert et al., 2015)— each of which independently increases
HIV risk (Sarah Larney, Bradley M Mathers, Tonia Poteat, Adeeba Kamarulzaman, & Louisa
Degenhardt, 2015; Willie, Stockman, Perler, & Kershaw, 2018). Despite potentially being able to
benefit from PrEP for HIV prevention, PrEP uptake among women with SUDs is low, in part because
women often underestimate their own HIV risk and are not aware of Pre-exposure prophylaxis (PrEP)
as a personally relevant option (Qin et al., 2020).

Behavior changes and adopting risk-reduction practices highly depend on people’s awareness and

perception of their degrees of HIV infection risk (Darbes, Crepaz, Lyles, Kennedy, & Rutherford, 2008;
Jorjoran Shushtari et al., 2019; Shiferaw et al., 2014). However, as a multifaceted concept, risk
perception could be directly or indirectly influenced by socioeconomic status, political and cultural
factors (Auli et al., 2013; Taylor‐Gooby & Zinn, 2006), and may be biased in different degrees and
directions. For instance, though many people engaging in sex work know that they can acquire HIV
through sexual contact, they focus on risk of infection from commercial, and not other partners (Bruce
et al., 2011). Psychosocial/cognitive models of HIV prevention claim that ‘incorrect’ risk perceptions,
which sometimes may even go as far as a sense of invulnerability, impede the development of
protective and preventive behaviors, such as condom use and HIV testing (Tenkorang & Maticka‐
Tyndale, 2013). Past studies have identified associations between risk perception and HIV prevention
behaviors, including delaying sexual debut, (Tenkorang, 2014) practicing abstinence (Gelibo,
Belachew, & Tilahun, 2013; Iriyama, Nakahara, Jimba, Ichikawa, & Wakai, 2007), using condoms
(Cederbaum, Gilreath, & Barman-Adhikari, 2014; Maharaj & Cleland, 2005), and adhering to daily oral
pre-exposure prophylaxis (PrEP) (Corneli et al., 2014; Haberer et al., 2017; van der Straten et al., 2014).
However, solid evidence on causal relationships between risk perception and behavior is limited due
to lack of longitudinal studies (Gerrard, Gibbons, & Bushman, 1996; Protogerou, Johnson, & Hagger,
2018).

While several previous double-blind randomized placebo-controlled PrEP trials showed no evidence
of sexual risk disinhibition and risk compensation (Baeten et al., 2012; Guest et al., 2008; Liu et al.,
2013) these RCTs are not ideal to evaluate sexual risk behaviors change as participants did not know
whether they were actually receiving PrEP or placebo. Therefore, studies simulating a real-world

scenario where participants are aware that they are taking PrEP are needed. Findings from a crosssectional study suggest that people with highest risk perception at baseline most likely to anticipate
increased HIV risk behaviors after starting PrEP (Shrestha et al., 2017). Studies involving women or
women with SUDs for PrEP are limited even though in many areas of the world women remain at
high-risk for HIV acquisition. As a result, this study maps the changes in risk behaviors among women
with SUDs in addiction treatment and enrolled in a preference controlled un-blinded clinical trial of
an HIV prevention decision aid. The objective is to evaluate whether these women experience changes
in HIV risk behaviors over time, including sexual and injecting risk behaviors, after assessing their
perceived HIV risk level. The primary hypothesis is that women who underestimated their personal
HIV risk at baseline will have greater risk behaviors reduction than women who accurately or overestimated their HIV risk.

Methods
Study design and setting
This is a secondary analysis of data derived from Project Options: Developing and Testing the Effect

of a Patient-Centered HIV Prevention Decision Aid on PrEP uptake for Women with Substance Use in
Treatment Settings, which has been described elsewhere (Qin et al., 2020).The original study is a
preference controlled un-blinded study, designed to inform, develop and test a patient-centered
decision aid about PrEP for women with SUDs.

Study sample and data collection
The sample was recruited using provider-, self-, and peer-referrals and followed at the APT

Foundation or research offices in New Haven, Connecticut for 1 year. Referred clients were then
screened for inclusion and exclusion criteria by a trained research assistant in a private room onsite.
This study enrolled 165 cis- or trans-female volunteers ≥18 years old who were self-reported HIVuninfected, had diagnosed SUDs, and were presenting for or currently enrolled in drug treatment.
Women were excluded if they were currently taking PrEP or were experiencing active withdrawal that
would interfere with consent processes.

The baseline study visit included an assessment of baseline sex- and drug-related HIV risk behavior
(modified from NIDA’s Risk Behavior Assessment), baseline preferences for PrEP as HIV prevention,
and preferences for receiving more information on PrEP. Those who opted to receive further
information were assigned to the “treatment arm”, and received the decision aid in English or Spanish,
facilitated by the trained research assistant using a standardized script and pre-printed handout or
pamphlet. Treatment arm participants also received a local resource guide for PrEP. Participants in
both arms received standard harm reduction counseling through the treatment center as standard of
care and were followed quarterly for 12 months with study visits to evaluate for HIV risk behaviors
and PrEP uptake. At each study visit, participants completed a brief structured interview with a trained
research assistant, and reviewed pill counts (only if on PrEP), and received an appointment card for
the subsequent visit.

Study measures
The main outcome of interest was HIV risk behavior score, which evaluated sex- and drug-related
HIV risk behaviors for participants. Participants were asked about different HIV risk behaviors,

including condomless sex with a man who injects drugs, condomless sex with a man who has sex with
men, condomless sex with a man who has HIV but is not virally suppressed, condomless sex with a
man with HIV status unknown, injection drug use and sharing equipment, exchanged sex. The risk
scale was modified from Denver HIV risk scale to conduct the assessment. Participants who scored 01 in the baseline risk assessment were classified as low risk for HIV. Others were classified as in medium
or high risk for HIV (medium:2-3 points, high:≥4 points). Participants were informed about their true
risk for HIV after baseline HIV risk assessment. Risk behavior assessments were also conducted at
quarterly follow-up visits.

The main exposure of interest was the accuracy of baseline HIV risk perception, which was calculated
based on HIV risk assessment and self-reported HIV risk perception. Participants were asked “How
likely are you to become infected by HIV right now?” and responded on a 5-point Likert scale from 1
(not at all likely) to 5 (extremely likely). For participants who were classified in high risk for HIV from
the HIV risk behavior score, if they selected 1-3 points in the Likert scale, they were then categorized
as underestimating their HIV risk, otherwise they were categorized as accurately or over- estimating
their HIV risk. For participants classified as medium risk for HIV, if they selected 1-2 points in the Likert
scale, they were then categorized as underestimating, otherwise they were categorized as accurately
or over- estimating their HIV risk. Participants in low HIV risk were all categorized as accurately or
over- estimating their risk. (Fig 1)

Figure 1. Categories of accuracy of HIV risk assessment
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Other covariates included age, race, marital status, education level, usual employment pattern, total
monthly income, which was analyzed continuously and dichotomized at the federal poverty level, HIV
concern, last time health check-up, would take PrEP if available, and receiving decision aid. For
individuals, the annual Income less than $12,800 was considered as below the federal poverty level
according to criteria from the Department of Health and Human Services (HHS)("Annual Update of
the HHS Poverty Guidelines," 2021). Chronic medical problems were defined as any serious physical
conditions that require regular care, (i.e.,medication, dietary restriction) preventing full advantage of
their abilities. Substance use disorders were evaluated at baseline using Addiction Severity Index
(ASI)(McLellan et al., 1992). Severe lifetime alcohol use was defined as having alcohol composite score
≥0.17. And severe lifetime drug use was defined as having drug composite score≥0.12. Severe
lifetime psychiatric disorder was defined as having ASI-P≥0.22. Hazardous drinking was evaluated
using the AUDIT (≥4 scores) at baseline (Conigrave, Hall, & Saunders, 2006).

Data Analysis
The baseline characteristics were described, including demographics, SUD severity, attitude toward
PrEP, HIV risk and HIV risk perception of the total participants. We conducted a comparison of baseline
characteristics between the low risk and medium/high risk groups. Continuous variables were
summarized by means and standard deviation and compared using Student’s t-test or Wilcoxon rank

sum test. Categorical variables were summarized by proportion and compared by chi-squared test
or Fisher’s exact test. Violin plots of distribution of HIV risk behavior score were performed using R
studio. Two-sided tests were used and statistical significance level was set to 0.05. All statistical
analyses were performed using SAS 9.4 statistical software.

Mixed effect models were applied to model the changes of HIV risk behaviors over time among
women with different HIV risk perceptions. The dependent variable to evaluate HIV risk behavior
change was HIV risk score reduction, which was coded as baseline HIV risk behavior assessment score
rd

th

th

th

minus HIV risk assessment score at the 3 , 6 , 9 , and 12 month, respectively. Three linear mixed
effects models were estimated with the REML method in a repeated measures design. Since the
correlations were expected to decrease as the assessment times were further removed from each
other, autoregressive(1) was used as covariance structure. These model takes subjects and time as
random effect, and is to estimate the fixed effect of accuracy of HIV risk perception and other
covariates on change of HIV risk behavior score, including age, race, education level, marital status,
income (below federal poverty level or not), receiving decision aid and time (ordinal). Interaction
between accuracy of HIV risk perception and time was taken into account.

Results
A total of 164 women with SUDs in treatment were enrolled in the study. Table 1-1 shows the
sociodemographic characteristics by baseline HIV risk. Age ranged from 19 to 61 years with a mean
age of 40.4±10.3 years. Over half of participants were single and about 22% were married. The majority
of participants were identified as White (73.2%) and Black (14.6%). This was consistent with the

demographic profile of people in drug treatment programs from SAMHSA National Survey on Drug
Use and Health (SAMHSA, 2018). Only 60 (36.6%) completed college or graduate education and others
completed 12 years education or less. Though 67.7% of participants were employed fulltime or parttime, over 70% of them had a total monthly income that fell below the federal poverty level.
Approximately half of participants had chronic medical problems which could potentially interfere
with their life. About 43.8% of the 32 women who responded to questions about alcohol use met
criteria for severe lifetime alcohol use. Among 89 women who responded to questions about drug
use, only one did not have severe lifetime drug use. 31 (54.4%) of the 57 women responding to AUDIT
met criteria for hazardous drinking. The mean age of women in the low-risk group (43.6±9.8) was
higher than that of women in the medium/high-risk group (38.2±10.2, p<0.001). A greater proportion
of women in the low-risk group had chronic medical problems compared to women in medium/highrisk group (60.3% vs. 44.2%, p=0.043). There was no significant difference observed between low and
medium/high HIV risk group in terms of marital status, race, education, usual employment pattern,
total monthly income.

HIV risk perception
Among the total participants, 29 (16.5%) reported that they were somewhat or extremely likely to be
infected by HIV, while the other 135 (82.3%) women thought they were not at all likely to be infected.
Compared to women at low HIV risk, women at medium/high HIV risk were more likely to self-report
that they were somewhat or extremely likely to be infected with HIV (27.1% vs. 4.4%, p<0.001). In terms
of the accuracy of HIV risk perception, 83 women underestimated their HIV risk at baseline, accounting
for 50.6% of total participants.

When asked about “How concerned are you about your risk for HIV”, the proportion of answering
“Not at all”, “Somewhat”, and “Extremely” was 67.1%, 25.7% and 7.2% respectively. More women
reported that they were not at all concerned about their HIV risk in low-risk group (p=0.001). Less
than half of women had their last regular checkup or physical with a health care provider within 6
months. When asked about whether they would take PrEP if it were available, only 25% answered “Yes”,
and about 45% answered they didn’t know what PrEP is. More people in the low-risk group did not
know about PrEP than in the medium/high-risk group (58.8% vs. 34.4%, p=0.004).

Table 1-1. Baseline characteristics among different HIV risk level groups
Total
Low
Median/High
P
N
%
N
%
N
%
Total
164 100.00
68
41.46
96
58.54
Age (Mean±SD）
40.40
10.33
43.58
9.78
38.15
10.15 <0.001
Marital status
0.469
Married
36
22.09
18
26.87
18
18.75
Single
85
52.15
33
49.25
52
54.17
Widowed/Separated/Divorced
42
25.77
16
23.88
26
27.08
Race
0.846
White
120
73.17
48
70.59
72
75.00
Black
24
14.63
12
17.65
12
12.50
Hispanic/Latino
3
1.83
1
1.47
2
2.08
Other
17
10.37
7
10.29
10
10.42
Education
0.968
College/Graduate
60
36.59
25
36.76
35
36.46
≤High school
104
63.41
43
63.24
61
63.54
Usual employment pattern
0.725
Fulltime/Part time
111
67.68
44
64.71
67
69.79
Retired/Disability/controlled
17
10.37
7
10.29
10
10.42
Unemployed
36
21.95
17
25.00
19
19.79
Total Monthly Income
793.50 836.00
815.00 857.00
768.50 836.00 0.521
(median, IQR)
Below federal poverty level
116
70.73
47
69.12
69
71.88 0.702
Chronic Medical Problems
83
50.92
41
60.29
42
44.21 0.043
Severe lifetime alcohol use
14
43.75
5
41.67
9
45.00 0.854
Severe lifetime drug use
88
98.88
28 100.00
60
98.36 1.000
Hazardous drinking
31
54.39
10
45.45
21
60.00 0.283
Severe lifetime psych disorder
110
91.67
41
85.42
69
95.83 0.087

Table 1-2. HIV related attitude and risk perception among different HIV risk groups
Total
Low
Median/High
N
%
N
%
N
%
Self-reported HIV risk
Not at all likely
135 82.32
65
95.59
70
72.92
Somewhat/Extremely Likely
29 17.68
3
4.41
26
27.08
HIV concern
Not at all concerned
102 67.11
52
83.87
50
55.56
Somewhat concerned
39 25.66
8
12.90
31
34.44
Extremely concerned
11
7.24
2
3.23
9
10.00
Last health check-up
Less than 6 months
79 48.17
38
55.88
41
42.71
6 months - 1 year
52 31.71
16
23.53
36
37.50
1-2 years
23 14.02
8
11.76
15
15.63
More than 2 years
10
6.10
6
8.82
4
4.17
Would take PrEP if available
Yes
41 25.00
13
19.12
28
29.17
Maybe
39 23.78
9
13.24
30
31.25
No/Unsure
11
6.71
6
8.82
5
5.21
Don’t know what PrEP is
73 44.51
40
58.82
33
34.38
Accuracy of HIV risk perception
Underestimated
83 50.61
0
0.00
83
86.46
Accurately/overestimated
81 49.39
68 100.00
13
13.54

P
<0.001

0.001

0.126

0.004

<0.001

Table 2. Comparison of HIV risk or protective behaviors between the two accuracy of perception groups at each time point
BL
M3
M6
M9
M12
a
b
A/O
U
A/O
U
A/O
U
A/O
U
A/O
U
N/%
N/%
P N/% N/%
P N/% N/%
P N/% N/%
P N/% N/%
P
Total (N)
81
83
65
62 0.395
51
52 0.967
53
45 0.143
55
46 0.100
80.25 74.50
62.96 62.65
65.43 54.22
67.90 55.42
41
80 <.001
28
34 0.185
19
35 0.002
22
28 0.041
27
28 0.237
Have sex without
condom
50.62
96.39
43.08 54.84
37.25 67.31
41.51 62.22
49.09 60.87
Exchange sex
1
15 <.001
2
4 0.433
0
4 0.118
1
2 0.592
2
4 0.407
Risk
behaviors
1.23
18.07
3.08 6.45
0.00 7.69
1.89 4.44
3.64 8.70
3
22 <.001
2
5 0.266
2
4 0.678
3
4 0.700
1
3 0.328
Share
injecting
equipment
3.70
26.51
3.08 8.06
3.92 7.69
5.66 8.89
1.82 6.52
Abstinence
30
14 0.005
25
15 0.036
27
11 0.007
24
14 0.173
46.15 22.58
49.02 28.85
50.94 24.44
43.64 30.43
Condom
8
14 0.126
6
6 0.972
4
6 0.505
3
5 0.463
12.31 22.58
11.76 11.54
7.55 13.33
5.45 10.87
Practicing harm reduction with
3
8 0.097
0
3 0.243
3
11 0.008
3
9 0.029
injecting
practice
4.62 12.90
0.00 5.77
5.66 24.44
5.45 19.57
Protective
methods
Regular HIV testing
5
5 1.000
5
9 0.267
3
7 0.179
3
8 0.055
7.69 8.06
9.80 17.31
5.66 15.56
5.45 17.39
Know your partners status
26
37 0.027
16
30 0.007
22
25 0.165
24
26 0.197
40.00 59.68
31.37 57.69
41.51 55.56
43.64 56.52
Drug treatment
52
53 0.414
47
44 0.233
48
36 0.136
46
40 0.640
80.00 85.48
92.16 84.62
90.57 80.00
83.64 86.96
1.0
3.0 <.001 0.0
1.0 0.001 0.0
1.0 <.001 0.0
2.0 0.003 1.0
1.5 0.005
c
HIV risk assessment
1.0
3.0
1.0
2.0
1.0
2.0
1.0
3.0
1.0
2.0
a-b. A/O: accurately/overestimated; U: underestimated
c. HIV risk assessment: HIV risk scores were summarized using median and IQR; p-values for it were generated from Wilcoxon rank sum test

HIV risk behaviors and protective behaviors
rd

th

th

th

Among the 164 women, the proportion who attended the 3 , 6 ,9 and 12 month visit was 77.4%,
62.8%, 59.8%, 61.6% respectively. And only 62 (37.8%) attended all quarterly visits. There was no
significant difference in attrition in terms of accuracy of risk perception at each visit.

According to Table 2, for HIV risk behaviors, a significantly greater number of women who
underestimated their HIV risk had had sex without a condom in the past 6 months than women who
th

accurately or overestimated their HIV risk at baseline (96.4% vs. 50.6%, p<0.001), the 6 month (67.3%
th

vs. 37.3%, p=0.002) and the 9 month (62.2% vs. 51.5%, p=0.041) of follow-up. However, the difference
rd

th

in HIV risk behaviors between the two groups disappeared in the 3 month and 12 month. The
proportion who had sex without a condom in the past 6 months among the underestimate group
rd

dropped from 96.4% at baseline to 54.8% at the 3 month, varied in the following visits but still kept
below 70% (Fig 2). Among the accurately/overestimated group, the proportion of women who had
sex without a condom in the past 6 months also had a slight decrease from around 50% to around
th

40%, but then went back to 49.1% in the 12 month (Fig 2). These findings indicate a decrease in
condomless sex over time among women who underestimated their HIV risk at baseline. At baseline,
the proportion of women who had exchanged sex (18.1% vs. 1.2%, p<0.001) and who shared drug
injecting equipment (26.5% vs. 3.70%, p<0.001) in the past 6 months were both greater in the
underestimated group than in the accurately/over-estimated group. Nevertheless, no significant
differences of exchanging sex and sharing injecting equipment between the underestimated group
and the accurately/overestimated group were observed at the subsequent visit. Among the
underestimated group, the proportions of women who exchanged sex and who shared injecting
rd

equipment declined after the 3 month (Fig 3 and Fig 4).

In terms of use of protective methods, very few women reported using condoms, practicing harm
reduction injecting behaviors (e.g., accessing syringe service programs, bleaching needles, syringes
or other injecting equipment), or having regular HIV tests. Compared to women in the underestimated
rd

group, more women who accurately or over-estimated their risk were abstinent from sex in the 3 ,
th

th

6 and 9 month. Interestingly, many women chose to know their partners’ HIV status and asked for
proof of test results, including over 50% of the underestimated group and 30%-40% in the
accurately/over-estimated group at each visit. Besides, the proportion who chose to know their
rd

partners’ HIV status was greater among women who underestimated their HIV risk in the 3 and the
th

6 month. In both risk perception groups, there were over 80% women reported they had drug
treatment with a medication, which is expected given our study setting. (Table 2)

For HIV risk assessment, the median of women who underestimated their HIV risk was significantly
higher than that of women who accurately or overestimated their risk at each time point (Table 2).
Moreover, the IQR of HIV risk score was larger among the underestimated group, indicating a more
disperse distribution. We also visualized the distribution of risk assessment scores using violin plots
and boxplots, and found a shift from baseline at each visit for women who underestimated their risk.
rd

The most obvious downward shift was from baseline to the 3 month. For the accurately/overestimate
group, the distributions were relatively stable at each time point. (Fig 5)
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Figure 2. Proportion of women having sex without condom by accuracy of risk perception groups at
each visit.
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Figure 3. Proportion of women exchanging sex by accuracy of risk perception groups at each visit.
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Figure 4. Proportion of women sharing injecting equipment by accuracy of risk perception groups at
each visit.

Figure 5. Violin plots of HIV risk behavior assessment scores at each time point, by accuracy of risk
perception

Mixed effect model
Model 1 was to target the effect of accuracy of HIV risk perception on HIV risk behavior change,
including time as a covariate to see if there was a trend of the change over time. Model 2 further
included baseline HIV risk level as another covariate. In Model 2, the significant effect of baseline HIV
risk on risk behavior change was detected while the significant effect of accuracy of risk perception
disappeared. This could because of the correlation between these two variables, given that the
classification of HIV risk perception accuracy was based on baseline HIV risk and self-reported
likelihood to get infected. As the aim is to target the effect of underestimating HIV risk, we finally built
Model 3 which dropped baseline HIV risk and included accuracy of HIV risk perception. Other
covariates in Model 3 including age, race, education level, marital status, income, receiving decision
aid and time. The interaction between accuracy of HIV risk perception and time was also incorporated.

The result of Model 3 was shown in Table 3, compared to women who accurately or over-estimated
their HIV risk, the reduction of HIV risk behavior scores among women who underestimated HIV risk
at baseline was 1.98 (95%CI:1.43-2.52, p<0.001) points greater, after adjusting for other covariates.
th

But this difference of HIV risk behavior scores reduction was 0.34 points smaller at the 6 month
(p=0.039). Women who were widowed, separated or divorced has 0.71 (95%CI:0.01-1.40, p=0.046)
greater decrease than women who were married.

Table 3. Results of the Mixed Effect Model
Effect
Estimate SE
P
95%CI
Underestimate HIV risk
1.98
0.28 <.001
(1.43,2.52)
Underestimate* Month 3
reference
Underestimate* Month 6
-0.34
0.16 0.039 (-0.66,-0.02)
Underestimate* Month 9
-0.13
0.17
0.433
(-0.47,0.20)
Underestimate* Month 3
-0.29
0.19
0.122
(-0.65,0.08)
Accurately/overestimate*Month 3
reference
Accurately/overestimate*Month 6
0.06
0.16
0.718
(-0.26,0.38)
Accurately/overestimate*Month 9
-0.07
0.16
0.647
(-0.39,0.24)

Accurately/overestimate*Month 12
3
6
Month
9
12
Decision aid
Age
Married
Marital status
Single
Widowed/Separated/Divorced
White
Black
Race
Hispanic/Latino
Other
College and graduate
Education level
High school
Below federal poverty level

-0.19
reference
0
0
0
0.14
0.02
reference
0.30
0.71
reference
-0.27
0.50
0.13
reference
-0.24
0.19

0.17
.

0.285

(-0.53,0.16)

0.561
0.259

(-0.32,0.60)
(-0.01,0.04)

0.313
0.046

(-0.29,0.89)
(0.01,1.40)

0.429
0.544
0.752

(-0.96,0.41)
(-1.13,2.13)
(-0.68,0.94)

0.332
0.465

(-0.72,0.24)
(-0.33,0.71)

.
0.23
0.01

.

.
0.30
0.35

.

.
0.35
0.83
0.41

.

.
0.25
0.26

Discussion

In this study of accuracy of HIV risk perception among 164 women with substance use disorders in
treatment, we tested the hypothesis that women who underestimated their HIV risk at baseline would
reduce their risk behavior over time. We observed a positive association between underestimating
HIV risk at baseline and reduction of HIV risk behaviors over time. Because participants in the
underestimate group would aware that their personal HIV risk was actually higher than they had
perceived after baseline assessment, which promoted them to reduce risk behaviors. While
participants in the accurately/overestimate group had already know their risk level well and thus were
less likely to change their behaviors. Though women who underestimated their HIV risk did reduce
their HIV risk behaviors to some extent over time, their HIV risk was still higher than women who
accurately or overestimated HIV risk at each subsequent visit. Some high-risk behaviors persisted.

Moreover, women in the underestimate group had the most remarkable change of risk behavior at

rd

the first visit (3 month), and this impact seems wore out slightly as time passed by. Thus, the greatest
impact of realizing exact HIV risk on the self-reported HIV risk behaviors was initially after baseline
with reduced behavioral change over time, indicating this impact on the change of HIV risk behaviors
may be short-term and fade if no other intervention is delivered. This could be well explained by the
law of diminishing returns, which was an economic law stating that if one input was increased while
all other inputs were fixed, a point will eventually be reached at which additions of the input yield
progressively smaller, or diminishing, increases in output. Therefore, acknowledge of personal HIV
risk level could be an initial motivation for behaviors change among high-risk population, but to
maintain this change more other efforts are desired, such as periodical counselling, motivational
interviewing and booster sessions for more regular contact. However, behavior change and behavior
change maintenance per se were difficult and affected by multifaceted factors, such as changing roles
of motives, elf-regulation, habits, resources (Kwasnicka, Dombrowski, White, & Sniehotta, 2016). Initial
behavior change was usually motivated by expectations of uncertain long-term outcomes, in this case,
changing behaviors to reduce HIV infection risk.

Condomless sex was a very common HIV risk behavior among participants, regardless of baseline HIV
risk perception. Though we observed a sharp decrease in condomless sex over time among the
“underestimate” group, the proportion was above 50% throughout the period of observation. This
could possibly be attributed to other determinants that affect women’s decisions of whether to use
condom, including violence, substance abuse, inability to negotiate with sexual partners. The hardest
thing about condoms was that they were partner dependent. Many women are unable to negotiate
condoms with their partners, limiting the potential for male condoms as a comprehensive HIV
prevention strategy. Previous studies have reported higher mortality due to violence among women
with SUDs compared to age-matched peers (Sarah Larney, Bradley M. Mathers, Tonia Poteat, Adeeba
Kamarulzaman, & Louisa Degenhardt, 2015). Many women with SUDs experience intimate partner

violence (IPV) when negotiating condom use (Qin et al., 2020). Limited social capital and economic
dependence on partners can also lead to unprotected sex (Muchomba, Chan, & El-Bassel, 2015). This
may also explain the greater reduction of HIV risk behaviors among widowed, separated or divorced
women than among married women.

The proportions of exchanging sex and sharing injecting equipment both declined among participants
at follow-up visits to the extent no different from women accurately or over- estimating their HIV risk
in this study. Potentially, individuals tend to attach more importance to exchanging sex and sharing
injecting equipment, relating higher HIV transmission risk to them, and feel easier to quit from them.
Interestingly, abstinent and knowing partners’ HIV status were the most frequently used protective
methods among participants, while taking regular HIV test was only adopted by few people.

Limitations

This study had a few limitations. Firstly, HIV risk behaviors were self-reported, which may be subject
to social desirability effect. In addition, it was a secondary analysis, as a result, data collected was not
tailor-made for the purposes of this analysis. If more detailed information related to multiple types of
HIV risk behaviors, such as the number of sex partners, partners’ HIV status, frequency of unprotected
sex, frequency of sharing drug injecting equipment, etc., could be collected and analyzed, we would
be powered to detect differences in these outcomes. Besides, only 37.8% of participants had attended
all follow-up visits. The result can be biased if loss-to-follow-up was related to HIV risk or accuracy
of risk perception. But the analysis showed that there was no association between missingness and
the accuracy of risk perception at each time point. Lastly, behavior change was associated with
multiple factors. Though some demographic characteristics was adjusted in the mixed effect model

when assess the impact of accuracy of HIV risk perception on behavior change, many other possible
confounders still can hardly be taken into account in the study, such as IPV.

Conclusion

In this study of HIV prevention decision-making among women with substance use disorders in
treatment, underestimating personal HIV risk was positively associated with reduction of HIV risk
behaviors. However, this effect was short-lived. Studies considering more information about other
confounders are needed to research the intensity and duration of this effect.
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